mp.weixin.qq.com· 触界生物·· 4 hours agoPickScore76
Novartis Cosentyx Approved in EU as World's First Targeted Therapy for Polymyalgia Rheumatica
诺华司库奇尤单抗获批，全球首款风湿性多肌痛靶向药诞生
In brief
On October 21, Novartis announced that the European Commission has approved Cosentyx (secukinumab) for adults with polymyalgia rheumatica (PMR) who had an inadequate response to glucocorticoids or who relapsed during glucocorticoid tapering. It is the first IL-17A inhibitor approved for PMR worldwide.
Why it matters
First targeted therapy approved for polymyalgia rheumatica, offering a new option for patients with inadequate glucocorticoid response or relapse during tapering.
Source: mp.weixin.qq.com · mp.weixin.qq.com